Golden State Equity Partners Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Golden State Equity Partners increased its holdings in Pfizer Inc. (NYSE:PFE) by 922.9% during the fourth quarter, Holdings Channel reports. The firm owned 18,188 shares of the biopharmaceutical company’s stock after acquiring an additional 16,410 shares during the quarter. Golden State Equity Partners’ holdings in Pfizer were worth $483,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in PFE. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $31,000. Czech National Bank raised its holdings in shares of Pfizer by 6.9% during the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after acquiring an additional 74,737 shares in the last quarter. Quent Capital LLC raised its holdings in shares of Pfizer by 15.0% during the 3rd quarter. Quent Capital LLC now owns 15,252 shares of the biopharmaceutical company’s stock worth $442,000 after acquiring an additional 1,987 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Pfizer by 48.9% during the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock worth $1,155,000 after acquiring an additional 13,097 shares in the last quarter. Finally, Diversified Trust Co raised its holdings in shares of Pfizer by 33.8% during the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock worth $3,285,000 after acquiring an additional 28,658 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on PFE. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim cut their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Price Performance

Shares of PFE stock opened at $26.51 on Monday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market capitalization of $150.20 billion, a price-to-earnings ratio of 35.82, a P/E/G ratio of 0.66 and a beta of 0.64. The stock has a fifty day simple moving average of $26.27 and a two-hundred day simple moving average of $27.86. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is currently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.